Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Establishing a Dengue Controlled Human Infection Model in Viet Nam (360G-Wellcome-212345_Z_18_Z)

Dengue is a mosquito-borne viral infection of major global significance. Millions of infections occur annually encompassing a wide clinical spectrum from inapparent infection to severe and fatal disease. Infection can be caused by any of four related serotypes but second infections with a different serotype are more likely to be associated with severity than primary infections. Although the first dengue vaccine was recently licensed, efficacy was only moderate despite demonstration of neutralising antibody responses to all serotypes, and there are now major safety concerns regarding priming of naïve vaccinees for severe disease later. To evaluate alternative vaccine candidates, NIAID has identified two attenuated challenge viruses with excellent safety profiles in dengue controlled human infection models (Dengue-CHIM) in US adults. We plan to collaborate with this experienced group to establish a similar Dengue-CHIM in Vietnam. However, since this is the first application in an endemic setting and no legal/regulatory framework exists, we propose an initial phase focused on bioethics/stakeholder engagement to develop a suitable regulatory framework, before moving forward to explore crucial research questions. An endemic setting Dengue-CHIM has great potential to advance dengue vaccine development and address the role of dengue immunity in the protection and pathogenesis of natural infection.


12 Mar 2018

Grant details
Amount Awarded 802357
Applicant Surname Wills
Approval Committee Internal Decision Panel
Award Date 2018-03-12T00:00:00+00:00
Financial Year 2017/18
Grant Programme: Title Controlled Human Infection Models
Internal ID 212345/Z/18/Z
Lead Applicant Prof Bridget Wills
Planned Dates: End Date 2022-01-31T00:00:00+00:00
Planned Dates: Start Date 2019-02-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East
Additional data added by GrantNav